Group 1 - The A-share market experienced a positive start to the Year of the Horse, with the Shanghai Composite Index rising by 0.87% and the Shenzhen Component Index increasing by 1.36% on February 24 [2] - The Hang Seng Index fell by 1.82%, and the Hang Seng Tech Index decreased by 2.13% on the same day [2] - As of February 24, there were 8 A+H listed companies experiencing an AH price inversion, where H-share prices exceeded A-share prices, representing approximately 4.6% of the total 174 A+H listed companies [3] Group 2 - The companies with AH price inversion include leading firms across various sectors such as new energy, banking, innovative pharmaceuticals, semiconductors, home appliances, mining, and machinery [4] - The phenomenon of AH price inversion is relatively rare, with no companies experiencing it a year ago on February 24, 2025 [2][4] - The average AH premium rate is typically around 125%, considering the 20% dividend tax on H-shares and the tax exemption for A-shares held for over a year [5] Group 3 - On February 24, the trading volume of A-shares for China Merchants Bank was 75.47 million shares, which is 7.7 times that of its H-shares at 9.8 million shares [5] - The market capitalization of China Merchants Bank is approximately 1.005 trillion yuan, with an AH premium rate of 0.89, indicating an 11% discount of A-shares relative to H-shares [5] - CATL, another leading company, saw its A-shares decline by 0.93% while H-shares fell by 3.13%, with A-share trading volume being 12.5 times that of H-shares [6] Group 4 - The AH premium index closed at 116.99 on February 24, indicating that A-shares are trading at a premium to H-shares, and this index has been on a downward trend since April 9, 2025 [11] - The index has dropped from a high of 144.85 to a low of 113.56, marking an eight-year low [11] - Analysts suggest that the recent trend of foreign capital favoring Hong Kong stocks may be influenced by the appreciation of the yuan, which could lead to a convergence of AH premiums [13] Group 5 - Morgan Stanley highlighted investment opportunities in sectors such as technology and cyclical recovery, particularly in leading companies within these fields [13] - Tianfeng Securities expressed a cautiously optimistic outlook for the Hong Kong market, suggesting a focus on value-oriented investments while maintaining growth as a secondary consideration [13]

Group 1 - The Hong Kong stock market experienced a decline in major tech stocks, with Tencent Holdings and Meituan dropping over 3%, while Alibaba, Baidu Group, and Xiaomi Group fell by 2% [1] - Southbound capital saw a reversal from net outflow to net inflow, with a rapid net inflow of HKD 3.1 billion in the last half hour before the market closed [1] - Significant buying activity was observed in the Hang Seng Technology Index ETF (513180.SH) and the Hang Seng Internet ETF (513330.SH), with over HKD 1 billion in large orders during a sharp intraday drop, indicating potential bullish sentiment towards Hong Kong tech assets [1] Group 2 - Investment opportunities are identified in Hong Kong tech-related ETFs, including the Hang Seng Technology Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and the Hong Kong Stock Connect Technology ETF (159101.SZ) [2] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet giants such as Alibaba, Baidu Group, Tencent Holdings, and NetEase, while the Hong Kong Stock Connect Technology ETF (159101.SZ) also includes leading innovative pharmaceutical companies [2] - These ETFs are listed on the Shanghai and Shenzhen stock exchanges, allowing A-share investors to trade flexibly with low entry barriers and without the need for cross-border accounts or currency exchange [2]

Core Insights - Pfizer has secured exclusive commercialization rights for the GLP-1 receptor agonist, Enogratide, in mainland China through a strategic partnership with Innovent Biologics [1][3] - The agreement allows Pfizer to pay up to $495 million, which includes upfront payments and milestone payments related to registration and sales [1] - The obesity rate among adults in China is currently 14.1%, highlighting the growing market potential for obesity treatments [3] Group 1: Market Dynamics - The Chinese obesity drug market is becoming increasingly competitive, with several multinational companies entering the space [1][3] - GLP-1 drugs are recognized as effective treatments for obesity, with six approved medications in China, five of which are GLP-1 based [3] - A price war has erupted among GLP-1 drugs, with significant price reductions from competitors like Novo Nordisk and Eli Lilly [3] Group 2: Strategic Moves - Innovent Biologics has opted to partner with Pfizer for the commercialization of Enogratide, leveraging Pfizer's strengths in market operations [5] - Pfizer is diversifying its business away from reliance on COVID-19 products, focusing on expanding its pipeline in obesity and oncology through external collaborations [5] - The penetration rate of GLP-1 drugs in China is currently below 1%, indicating substantial growth potential as market education efforts increase [5]

恒生科技指数ETF（513180.SH）恒生互联网ETF（513330.SH）开年走低，权重股阿里巴巴、腾讯控 股、小米集团等再陷调整。 消息面上，春节假期，美联储降息预期下修，港股作为对外部流动性极为敏感的市场，节后表现较弱。 美国当地时间2月18日下午，美联储公布1月议息会议纪要，美联储官员对未来政策展望呈现巨大分歧， 市场认为短期内降息节奏可能放缓；2月19日，美国公布的初请失业金人数显示美国就业市场仍保持一 定韧性，而就业是降息周期中美联储重点关注的指标，基于此市场降低对美联储降息预期；2月20日， 美国公布的12月PCE高于预期，强化美联储暂缓降息预期，市场对6月降息预期下降至45.6%，降息预期 推迟至7月。 招商证券张夏团队点评称：短期美联储政策预期反复有扰动，但流动性冲击最大的阶段已经过去，且美 联储仍处降息周期，一旦降息预期重新稳固，港股作为离岸市场将显著受益；且春节后随着南下资金的 流入，也将为港股带来流动性支持。 投资工具方面，持续关注港股科技相关ETF：恒生科技指数ETF（513180.SH）、恒生互联网ETF （513330.SH）、港股通科技ETF基金（159101.SZ）。其中， ...

证券研究报告·宏观报告·宏观周报 金融产品周报 20260207 海外市场流动性有企稳迹象，情绪或会好转 【勘误版】 [Table_Summary] 基金规模统计：（2026.2.2-2026.2.6） 市场行情展望：（2026.2.9-2026.2.13） 基金配置建议： 2026 年 02 月 24 日 《商品流动性冲击之后，哪些品种被 "错杀"？》 2026-02-04 《黄金 ETF，2026 年 1 月复盘与 2 月 证券分析师 芦哲 展望》 执业证书：S0600524110003 luzhe@dwzq.com.cn 证券分析师 唐遥衎 2026-02-03 执业证书：S0600524120016 东吴证券研究所 1 / 20 tangyk@dwzq.com.cn 相关研究 请务必阅读正文之后的免责声明部分 [Table_Tag] ◼ 权益类 ETF 基金规模变化统计：规模变化排名前三名的权益类 ETF 类 型分别为：规模指数 ETF（154.06 亿元），跨境行业指数 ETF（66.24 亿 元），策略指数 ETF（53.71 亿元）；基金规模变化排名后三名的权益 类 ETF 类型分别为：跨境规模 ...

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]

刘刚认为，短期看，市场或有超调，回撤后短期可能存在向上修复空间。中期看，基准情形下，我们判 断港股盈利增长3%~4%与景气结构主线情绪修复，或推动恒指中枢上行至28000~29000点左右。 2月24日，为港股市场马年第三个交易日，恒生科技指数开盘重回跌势，指数权重股腾讯控股、阿里巴 巴、百度集团、华虹半导体等股价再度调整。 自2月以来，港股尤其是恒生科技指数，走势较弱，源自三方面的变化：（1）基本面偏弱、市场担忧流 动性收紧；（2）投资者重新评估AI资本开支叙事逻辑；（3）权重股（腾讯、阿里巴巴等）短期因AI 应用现金补贴遭遇"逆风"，拖累科技板块表现。 展望港股后市，中金公司（601995）研究部董事总经理、首席海外与港股策略分析师刘刚表示，"信用 周期决定指数空间，产业趋势决定结构强弱，流动性放大波动"。 招商证券策略研究团队表示，"春节后，随着南下资金的流入，也将为港股带来流动性支持。结构上， 推荐科技（AI算力与应用）、非银（保险）与红利。"其中，恒生科技的估值底和政策底逐步夯实，但 盈利底和流动性拐点仍需确认，重点关注未来市场对恒生科技盈利预期的修正，以及美联储政策预期变 化对恒生科技的催化。一旦 ...

各大券商分析师春节"连轴转" 每经记者｜王海慜 每经编辑｜何小桃 赵云 宋思艰 2026年马年春节假期，虽然A股休市，但资本市场却热度不减。 各大券商的分析师们开启"加班模式"，以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的连续七天新春专题路演，到中信证券聚焦AI大模 型的系列电话会，再到多家机构跟踪春节消费动态，头部与中小券商均紧抓假期窗口输出市场观点。 《每日经济新闻》记者注意到，今年春节加班路演已经成为各券商研究所的常态，无论是中小券商还是头部券商都在假期中继续"营业"，"加更"观点。 港股马年开市两天呈现结构性行情，2月20日开市首日AI大模型、机器人板块逆势大涨，创新药、氢能概念股表现亮眼。2月20日和23日，恒生科技指数 走势先抑后扬，迎来马年"开门红"。 同时业内预计，美国此次关税裁定落地利好非美市场资产，叠加A股春节效应的历史正向表现，市场对马年节后"红包行情"的延续抱有较高期待。 截图来源：网络 最近，兴业证券策略首席张启尧的春节路演计划表在圈内刷屏：从大年初一至初七，他和团队同事一起每天15:00准时与投资者连线。 这场名为"新春专题系列"的直播，内容涵盖港股情绪研究框架、20 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 每经记者｜王海慜 每经编辑｜赵云 2026年马年春节假期，虽然A股休市，但资本市场却热度不减。 各大券商分析师们开启"加班模式"，以高频路演、专题研报填补假期信息真空。从兴业证券策略团队的 连续七天新春专题路演，到中信证券聚焦AI（人工智能）大模型的系列电话会，再到多家机构跟踪春 节消费动态，头部与中小券商均紧抓假期窗口输出市场观点。 港股马年开市两天呈现结构性行情，2月20日开市首日AI大模型、机器人板块逆势大涨，创新药、氢能 概念股表现亮眼。2月23日，港股大涨。截至收盘，恒生指数涨2.53%，恒生科技指数涨3.34%。 此外，业内预计，美国最高法院关税裁定利好非美市场资产，叠加A股春节效应的历史正向表现，市场 对马年春节后"红包行情"的延续抱有较高期待。 机器人、创新药大热 这场名为"新春专题系列"的直播，内容涵盖港股情绪研究框架、2026年十大产业趋势、全球估值比较、 全球产业映射、出海深度报告等多个维度。张启尧及其团队试图在春节假期这一A股市场"空窗期"，通 过高频的观点输出，抢占投资者的注意力高地。 这并非行业个例。多家机构 ...

阿里、腾讯、美团等被总结为建议调出的"老登恒生"成分股。同时，恒生生物科技指数也在当日逆市收 涨0.96%，另外，石油股也出现走强。 值得留意的是，虽然港股互联网主题ETF、恒生科技ETF等节前资金流入最多的ETF并未迎来涨势，但 表现强势的个股也有公募基金的布局身影，次新股以打新的方式布局，而表现强势板块则在此前已有主 动权益基金的加仓迹象。 2月22日，节后首个交易日，恒指和恒生科技虽然没有收涨，但AI概念股的涨势如期而至。 2月20日，港股三大指数集体收跌。其中，恒生科技收跌2.91%，恒生指数收跌1.10%，而恒生国企指数 收跌1.22%。相较于恒生科技的继续下挫，港股上市的AI概念次新股却迎来上涨，网友也出现了调整恒 生科技部分成分股的建议。 小米、中芯国际、比亚迪、腾讯、快手等成分股也在去年四季度被主动权益基金减持，不过，美团在去 年四季度得到主动权益基金增持超过1700万股。 石油、创新药板块走强 港股AI概念股大涨 截至2月20日收盘，智谱延续强势表现，收涨42.72%，报725港元；MiniMax也同样收涨14.52%，报970 港元。两大AI龙头盘中最高市值双双突破3000亿港元，与上市初 ...